6-甲基萘-1-羧酸 | 6315-19-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 6-甲基萘-1-羧酸
• 中文别名: 6-甲基-1-萘甲酸
• 英文名称: 6-Methyl-[1]naphthoesaeure
• 英文别名: 6-methyl-1-naphthoic acid；6-Methyl-naphthoesaeure-(1)；6-methylnaphthoic acid；6-Methylnaphthalene-1-carboxylic acid
• CAS: 6315-19-1
• 化学式: C₁₂H₁₀O₂
• 分子量: 186.21
• InChiKey: CQEFVJGDGBHWKH-UHFFFAOYSA-N

物化性质

• 熔点：
  176.5-177 °C
• 沸点：
  380.1±11.0 °C(Predicted)
• 密度：
  1.222±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  6-甲基萘-1-羧酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 苯 为溶剂， 反应 4.0h， 以96%的产率得到6-甲基-1-萘甲酰氯
  参考文献：
  名称：

  New Synthesis of Vaulted Biaryl Ligands via the Snieckus Phenol Synthesis

  摘要：

  In an effort to develop a synthesis of the VAPOL ligand that avoids the use of a chromium carbene complex, a route vias examined that involved the annulation of a naphthalene carboxamide via the method of Snieckus. The latter derivatives could be converted in a two-step sequence to 2-phenyl-4-phenanthrols in 6D-72% overall yields. The utility of this method for the synthesis of VAPOL derivatives is demonstrated in the synthesis of (S)-7,7'-dimethyl-VAPOL.

  DOI：

  10.1021/ol047852e
• 作为产物：
  描述：

  糠酸（呋喃甲酸） 、 甲苯 在 三氯化铝 作用下， 以11%的产率得到6-甲基萘-1-羧酸
  参考文献：
  名称：

  二取代的新型氨基-芳基-哌啶类肾素抑制剂的发现和制备。

  摘要：

  最近，反式-二取代的氧代-芳基-哌啶已被确认为小分子非肽类肾素抑制剂，可调节高血压。在这里，我们报告发现和制备新型新型的顺式-二取代的氨基-芳基-哌啶类作为对映体的混合物，这些对映体是有效的体外肾素抑制剂，并且在双转基因小鼠模型中具有体内降压活性。

  DOI：

  10.1016/j.bmc.2004.09.056

文献信息

• The Substituent Effect. XI. Solvolysis of 5-, 6-, and 7-Substituted 1-(1-Naphthylethyl) Chlorides
  作者：Yuho Tsuno、Masami Sawada、Takahiro Fujii、Yoshihiko Tairaka、Yasuhide Yukawa

  DOI：10.1246/bcsj.48.3356

  日期：1975.11

  Fourteen 5-, 6-, and 7-substituted 1-(1-naphthylethyl) chlorides were prepared and the solvolysis rates were determined in 80% (v/v) aqueous acetone at 45 °C. The effects of −R substituents at respective positions were treated on the basis of the equation, logk⁄k0=ρiσi+ρx+σx+=ρ(Cijσi+qrij+σπ+). The position dependency of the inductive effect was given by Cij(=ρi⁄ρi,4α); C3α=1.37, C4α=1.00, C5α=0.75, C6α=0.57, and C7α=0.72. The Cij values appear to be correlated with Dewar’s simplified field function 1/rij. The position dependency of Pi-electronic effect given by the ratio ρπ+⁄ρi,4α=qr·ij+ was consistent with the prediction from the MO indices, such as Forsyth’s Δqij(ArCH2+ parameters. The same treatment was applied also to three other naphthalene reactivities, detritiation, pKa of α-naphthoic acids and pKa of naphthylammonium ions. The linear ρi–ρi relation holds among these reactions, suggesting a reaction-independent scheme of the inductive transmission. The qr·ij+ values vary at conjugate positions with reaction but not at non-conjugate positions irrespective of reactions. The results are discussed in comparison with those of relevant treatments.

  制备了十四个5-、6-和7-取代的1-(1-萘乙基)氯化物，并在45°C下，80%（体积/体积）的乙酸水溶液中测定了其溶剂分解速率。基于方程logk⁄k0=ρiσi+ρx+σx+=ρ(Cijσi+qrij+σπ+)，处理了在相应位置上的−R取代基的影响。诱导效应的位置依赖性由Cij(=ρi⁄ρi,4α)给出；C3α=1.37，C4α=1.00，C5α=0.75，C6α=0.57，C7α=0.72。Cij值似乎与Dewar的简化场函数1/rij相关。由比率ρπ+⁄ρi,4α=qr·ij+给出的π电子效应的位置依赖性与从MO指数（如Forsyth的Δqij(ArCH2+参数）的预测一致。同样的处理也应用于其他三种萘的反应性：脱氢、α-萘甲酸的pKa和萘甲基铵离子的pKa。在这些反应中，线性ρi–ρi关系成立，表明诱导传递的反应独立方案。qr·ij+值在共轭位置随反应变化，但在非共轭位置不随反应变化。结果在与相关处理的比较中进行了讨论。
• Rh-Catalyzed Annulation of Benzoic Acids, Formaldehyde, and Malonates via <i>ortho</i>-Hydroarylation to Indanones
  作者：Shuling Yu、Ningning Lv、Chao Hong、Zhanxiang Liu、Yuhong Zhang

  DOI：10.1021/acs.orglett.0c02986

  日期：2020.11.6

  A three-component reaction from readily available low-cost materials of benzoic acids, formaldehyde, and malonates for the preparation of indanones by rhodium catalysis is reported. The annulation is initiated by an ortho-hydroarylation of benzoic acids, and a Lewis acid is not required. The solvent has a significant influence to the reaction, and 2-substituted or nonsubstituted indanones are obtained

  据报道，由廉价的苯甲酸，甲醛和丙二酸酯的廉价原料进行三组分反应，可通过铑催化制备茚满酮。通过苯甲酸的邻-氢芳基化来引发环化，并且不需要路易斯酸。溶剂对反应有重大影响，并且通过改变溶剂获得2-取代或未取代的茚满酮。
• INHIBITING FATTY ACID SYNTHASE (FASN)
  申请人：Forma Therapeutics, Inc.

  公开号：EP3636637A1

  公开（公告）日：2020-04-15

  The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.

  本公开涉及FASN的抑制剂。这些化合物可用于治疗与FASN抑制相关的疾病或疾病。例如，本公开涉及用于抑制FASN的化合物和组合物，治疗、预防或改善与FASN抑制相关的疾病或疾病的方法，以及这些化合物的合成方法。
• Heterocyclic derivatives
  申请人：Imperial Chemical Industries PLC

  公开号：US05098930A1

  公开（公告）日：1992-03-24

  The invention concerns a heterocyclic derivative of the formula I, ##STR1## wherein Ar.sup.1 is optionally substituted phenyl or naphthyl; A.sup.1 is (1-6C)alkylene, (3-6C)alkenylene, (3-6C)alkynylene or cyclo-(3-6C)alkylene; Ar.sup.2 is optionally substituted phenylene, or a 6 membered heterocyclene moiety containing up to three nitrogen atoms; R.sup.1 is hydrogen, (1-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl, cyano-(1-4C)alkyl or (2-4C)alkanoyl, or optionally substituted benzoyl; and R.sup.2 and R.sup.3 together form a group of the formula -A.sup.2 -X-A.sup.3 - wherein each of A.sup.2 and A.sup.3 is (1-4C)alkylene and X is oxy, thio, sulphinyl, sulphonyl or imino; or a pharmaceutically-acceptable salt thereof. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.

  该发明涉及式I的杂环衍生物，其中Ar.sup.1是可选择取代的苯基或萘基；A.sup.1是(1-6C)烷基，(3-6C)烯基，(3-6C)炔基或环-(3-6C)烷基；Ar.sup.2是可选择取代的苯基，或含有最多三个氮原子的6元杂环基；R.sup.1是氢，(1-6C)烷基，(3-6C)烯基，(3-6C)炔基，氰基-(1-4C)烷基或(2-4C)烷酰基，或可选择取代的苯甲酰基；而R.sup.2和R.sup.3共同形成式-A.sup.2-X-A.sup.3-的基团，其中A.sup.2和A.sup.3中的每一个是(1-4C)烷基，X是氧，硫，亚硫酰基，磺酰基或亚胺基；或其药用可接受盐。该发明的化合物是5-脂氧合酶的抑制剂。
• DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS
  申请人：Matsuyama Hironori

  公开号：US20100004438A1

  公开（公告）日：2010-01-07

  An object of the present invention is to provide a medicinal drug much improved in anti tumor activity and excellent in safety. According to the present invention, there is provided a medicinal drug containing a compound represented by the following general formula (1) or a salt thereof as an active ingredient: [Formula 1] wherein X 1 represents a nitrogen atom or a group —CH═, R 1 represents a group -Z-R 6 , in which Z represents a group —CO—, a group —CH(OH)— or the like, R 6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R 2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents [Formula 2] wherein R 3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R 4 represents an imidazolyl lower alkyl group or the like.

  本发明的一个目的是提供一种在抗肿瘤活性方面大大改进且安全性优异的药物。根据本发明，提供了一种包含以下一般式（1）所表示的化合物或其盐作为活性成分的药物：[式1]其中X1代表氮原子或基团—CH═，R1代表一个基团-Z-R6，其中Z代表基团—CO—，基团—CH(OH)—或类似的基团，R6代表一个含有1至4个氮原子、氧原子或硫原子的5至15个成员的单环、双环或三环饱和或不饱和杂环基团，R2代表氢原子或卤原子，Y代表基团—O—，基团—CO—，基团—CH(OH)—或低碳烷基基团，A代表[式2]其中R3代表氢原子、低碳氧基基团或类似基团，p代表1或2，R4代表咪唑基低碳基团或类似基团。